Compare APPF & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPF | TGTX |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.5B |
| IPO Year | 2015 | 2008 |
| Metric | APPF | TGTX |
|---|---|---|
| Price | $204.24 | $53.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $236.04 | $69.71 |
| AVG Volume (30 Days) | 217.5K | ★ 1.4M |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 2.36 | 0.17 |
| Revenue | ★ $950,822,000.00 | $2,785,000.00 |
| Revenue This Year | $18.19 | $55.80 |
| Revenue Next Year | $17.45 | $37.28 |
| P/E Ratio | ★ $83.63 | $328.53 |
| Revenue Growth | ★ 19.72 | N/A |
| 52 Week Low | $142.56 | $26.76 |
| 52 Week High | $264.87 | $59.30 |
| Indicator | APPF | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 52.86 |
| Support Level | $200.57 | $51.76 |
| Resistance Level | $227.62 | $58.26 |
| Average True Range (ATR) | 7.13 | 2.13 |
| MACD | -2.23 | -0.16 |
| Stochastic Oscillator | 35.55 | 56.39 |
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.